Completed PHASE2 INTERVENTIONAL 2-arm NCT00690482

Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus)

A 4 Week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: AstraZeneca

Conditions Moderate to Severe COPD

Interventions AZD1981 Placebo

Updated 7 times since 2017 Last updated: Dec 13, 2013 Started: May 31, 2008 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00690482, this PHASE2 trial focuses on Moderate to Severe COPD and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arhus C, Denmark , Bojnice, Slovakia , Hellerup, Denmark , Hvidovre, Denmark , Krakow, Poland , Liptovský Hrádok, Slovakia , Lublin, Poland , Lund, Sweden , Ostrów Wielkopolski, Poland , Pleven, Bulgaria and 11 more locations